Anti-CD30 CAR T cells

GENETIC2 trials

Sponsors

Peking University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Conditions

Adult T-Cell Lymphoma/LeukaemiaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaHodgkin LymphomaLymphomasNK/T-cell LymphomaPeripheral T Cell Lymphoma

Phase 1

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

Peking UniversityLymphomas

Start: 2014-03-31End: 2017-10-31Target: 20Updated: 2014-10-24

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAdult T-Cell Lymphoma/Leukaemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma +3

Start: 2019-07-03End: 2023-01-01Target: 50Updated: 2019-08-07

Related Papers

415. First-In-Patient Proof of Safety and Efficacy of a 4th Generation Chimeric Antigen Receptor-Modified T Cells for the Treatment of Relapsed or Refractory CD30 Positive Lymphomas

Molecular Therapy2015-05-018 citations